Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 186

2.

Efficacy and tolerability of the new antiepileptic drugs: commentary on the recently published practice parameters.

Panayiotopoulos CP, Benbadis SR, Covanis A, Dulac O, Duncan JS, Eeg-Olofsson O, Ferrie CD, Grünewald RA, Kasteleijn-Nolst Trenite DG, Koutroumanidis M, Martinovic Z, Newton RW, Parker AP, Salas-Puig J, Sander JW, Shorvon S, Watanabe K, Whitehouse WP, Youroukos S.

Epilepsia. 2004 Dec;45(12):1646-9; author reply 1649-51. No abstract available.

3.

The International Lamotrigine pregnancy registry update for the epilepsy foundation.

Cunnington MC.

Epilepsia. 2004 Nov;45(11):1468. No abstract available.

4.

Worsening of seizures by oxcarbazepine in juvenile idiopathic generalized epilepsies.

Gelisse P, Genton P, Kuate C, Pesenti A, Baldy-Moulinier M, Crespel A.

Epilepsia. 2004 Oct;45(10):1282-6.

5.

Navigating toward fetal and maternal health: the challenge of treating epilepsy in pregnancy.

Tomson T, Perucca E, Battino D.

Epilepsia. 2004 Oct;45(10):1171-5.

6.

Levetiracetam safety profiles and tolerability in epilepsy patients.

Briggs DE, French JA.

Expert Opin Drug Saf. 2004 Sep;3(5):415-24. Review.

PMID:
15335297
7.

Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study.

de Haan GJ, Edelbroek P, Segers J, Engelsman M, Lindhout D, Dévilé-Notschaele M, Augustijn P.

Neurology. 2004 Aug 10;63(3):571-3.

PMID:
15304599
8.

The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.

Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B.

Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9861-6. Epub 2004 Jun 21.

9.

The AED (antiepileptic drug) pregnancy registry: a 6-year experience.

Holmes LB, Wyszynski DF, Lieberman E.

Arch Neurol. 2004 May;61(5):673-8.

PMID:
15148143
10.

Vigabatrin, the GABA-transaminase inhibitor, damages cone photoreceptors in rats.

Duboc A, Hanoteau N, Simonutti M, Rudolf G, Nehlig A, Sahel JA, Picaud S.

Ann Neurol. 2004 May;55(5):695-705.

PMID:
15122710
11.

Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society.

French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, Theodore WH, Bazil C, Stern J, Schachter SC, Bergen D, Hirtz D, Montouris GD, Nespeca M, Gidal B, Marks WJ Jr, Turk WR, Fischer JH, Bourgeois B, Wilner A, Faught RE Jr, Sachdeo RC, Beydoun A, Glauser TA; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology; Quality Standards Subcommittee of the American Academy of Neurology; American Epilepsy Society.

Neurology. 2004 Apr 27;62(8):1261-73. Review.

PMID:
15111660
12.

Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society.

French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, Theodore WH, Bazil C, Stern J, Schachter SC, Bergen D, Hirtz D, Montouris GD, Nespeca M, Gidal B, Marks WJ Jr, Turk WR, Fischer JH, Bourgeois B, Wilner A, Faught RE Jr, Sachdeo RC, Beydoun A, Glauser TA; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology; Quality Standards Subcommittee of the American Academy of Neurology; American Epilepsy Society.

Neurology. 2004 Apr 27;62(8):1252-60. Review.

PMID:
15111659
13.

Efficacy and tolerability of the new antiepileptic drugs, II: Treatment of refractory epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society.

French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, Theodore WH, Bazil C, Stern J, Schachter SC, Bergen D, Hirtz D, Montouris GD, Nespeca M, Gidal B, Marks WJ Jr, Turk WR, Fischer JH, Bourgeois B, Wilner A, Faught RE Jr, Sachdeo RC, Beydoun A, Glauser TA; American Academy of Neurology Therapeutics and Technology Assessment Subcommittee; American Academy of Neurology Quality Standards Subcommittee; American Epilepsy Society Therapeutics and Technology Assessment Subcommittee; American Epilepsy Society Quality Standards Subcommittee.

Epilepsia. 2004 May;45(5):410-23. Review. Erratum in: Epilepsia. 2004 Nov;45(11):1299.

14.

Efficacy and tolerability of the new antiepileptic drugs, I: Treatment of new-onset epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society.

French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, Theodore WH, Bazil C, Stern J, Schachter SC, Bergen D, Hirtz D, Montouris GD, Nespeca M, Gidal B, Marks WJ Jr, Turk WR, Fischer JH, Bourgeois B, Wilner A, Faught RE Jr, Sachdeo RC, Beydoun A, Glauser TA; American Academy of Neurology Therapeutics and Technology Assessment Subcommittee; American Academy of Neurology Quality Standards Subcommittee; American Epilepsy Society Quality Standards Subcommittee; American Epilepsy Society Therapeutics and Technology Assessment Subcommittee.

Epilepsia. 2004 May;45(5):401-9. Review.

15.

Efficacy and tolerability of levetiracetam in patients with therapy-resistant epilepsy and learning disabilities.

Huber B, Bömmel W, Hauser I, Horstmann V, Liem S, May T, Meinert T, Robertson E, Schulz L, Seidel M, Tomka-Hoffmeister M, Wagner W.

Seizure. 2004 Apr;13(3):168-75.

16.
17.

The impact of pregnancy and childbirth on the metabolism of lamotrigine.

Pennell PB, Newport DJ, Stowe ZN, Helmers SL, Montgomery JQ, Henry TR.

Neurology. 2004 Jan 27;62(2):292-5. Erratum in: Neurology. 2010 Jun 15;74(24):2028.

PMID:
14745072
18.

Unusual side-effects due to clobazam: a case report with genetic study of CYP2C19.

Parmeggiani A, Posar A, Sangiorgi S, Giovanardi-Rossi P.

Brain Dev. 2004 Jan;26(1):63-6.

PMID:
14729419
19.

Use of levetiracetam in a population of patients aged 65 years and older: a subset analysis of the KEEPER trial.

Ferrendelli JA, French J, Leppik I, Morrell MJ, Herbeuval A, Han J, Magnus L.

Epilepsy Behav. 2003 Dec;4(6):702-9.

PMID:
14698704
20.

Levetiracetam reduces spike-wave density and duration during continuous EEG monitoring in patients with idiopathic generalized epilepsy.

Gallagher MJ, Eisenman LN, Brown KM, Erbayat-Altay E, Hecimovic H, Fessler AJ, Attarian HP, Gilliam FG.

Epilepsia. 2004 Jan;45(1):90-1. No abstract available.

Supplemental Content

Support Center